Telix (ASX:TLX) share price down 4% despite new deal

Biopharma Telix Pharmaceuticals Ltd (ASX: TLX) share price is trading lower this morning, despite the company announcing the completion of its acquisition of Swiss-based company, TheraPharm.

At the same time, the company also announced that TheraPharm has now completed an intellectual property (IP) agreement with the University of Southampton in the United Kingdom.

At the time of writing, the Telix share price is trading at $3.59, down 4.27%.

About the TheraPharm acquisition

Telix advised it has now acquired all of the issued capital of TheraPharm for the final upfront consideration of €10.2 million (A$16.5 million). This was done at a price of $3.75 per share. That deal was first announced in late November.

Telix also…